Tempest Therapeutics, Inc.
TPST
$0.91
-$0.08-7.93%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 283.35% | 63.95% | 11.40% | 1.10% | -76.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.16% | -49.35% | -70.71% | -65.91% | -50.26% |
| Operating Income | -10.16% | 49.35% | 70.71% | 65.91% | 50.26% |
| Income Before Tax | 33.37% | -155.03% | 70.89% | 66.74% | 17.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 33.37% | -155.03% | 70.89% | 66.74% | 17.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 33.37% | -155.03% | 70.89% | 66.74% | 17.76% |
| EBIT | -10.16% | 49.35% | 70.71% | 65.91% | 50.26% |
| EBITDA | -10.45% | 49.59% | 71.07% | 66.22% | 50.15% |
| EPS Basic | 83.35% | 19.80% | 81.29% | 85.13% | 62.50% |
| Normalized Basic EPS | 71.95% | 84.03% | 81.29% | 85.13% | 77.75% |
| EPS Diluted | 83.35% | 19.80% | 81.29% | 85.13% | 62.50% |
| Normalized Diluted EPS | 71.95% | 84.03% | 81.29% | 85.13% | 77.75% |
| Average Basic Shares Outstanding | 300.32% | 217.99% | 55.62% | 123.67% | 119.28% |
| Average Diluted Shares Outstanding | 300.32% | 217.99% | 55.62% | 123.67% | 119.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |